FY2024 Earnings Forecast for MIRM Issued By Leerink Partnrs

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.60) for the year, up from their previous forecast of ($1.63). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q4 2024 earnings at ($0.24) EPS and FY2025 earnings at ($0.83) EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the prior year, the firm posted ($0.57) earnings per share. The company’s revenue was up 89.4% compared to the same quarter last year.

Several other brokerages have also issued reports on MIRM. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners lifted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $47.53 on Friday. The firm’s fifty day simple moving average is $43.76 and its two-hundred day simple moving average is $41.53. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $49.27. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -23.53 and a beta of 0.98.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now directly owns 2,926 shares of the company’s stock, valued at $125,291.32. The trade was a 20.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,706 shares of company stock worth $875,697 over the last quarter. 22.87% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. Amalgamated Bank raised its stake in Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the period. R Squared Ltd acquired a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth approximately $69,000. Mirae Asset Global Investments Co. Ltd. grew its position in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. Avanza Fonder AB acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at approximately $189,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $215,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.